Immunotherapy breakthrough now approved as standard of care for advanced melanoma

A ‘game changer,’ says UCLA’s Dr. Antoni Ribas, the study’s principal investigator

keytruda_mechanism

Keytruda or Pembrolizumab mechanism http://bit.ly/1QTa0FV

A first-of-its-kind (anti-PD-1) immunotherapy was approved today by the U.S. Food & Drug Administration as first-line treatment for metastatic melanoma—allowing greater access to this therapy for patients without having to previously receive other prior treatments.

Co-developed by UCLA Jonsson Comprehensive Cancer member Dr. Antoni Ribas, the drug pembrolizumab has signaled a paradigm shift in the way melanoma is treated. The protein works by blocking the immune system’s brakes, thereby allowing its T cells to recognize and attack cancer cells.

Pembrolizumab (marketed under the brand name Keytruda®) originally received accelerated approval by the FDA in 2014 for metastatic melanoma. Until recently, pembrolizumab was only given to patients who were no longer responding to ipilimumab, the current standard first-line therapy for people with the disease. Ipilimumab works similarly to pembrolizumab by binding to another immune molecule, called CTLA-4, which also blocks T cell activity.

This approval is based on the results of a recent study by Ribas and a team of researchers from 16 countries who found that pembrolizumab, compared to ipilimumab, has less severe side effects, improved tumor responses, enhanced the duration of responses, and extended the patient’s life.

“We are delighted that we found that pembrolizumab is superior to ipilimumab as first-line therapy by improving responses and survival,” said Ribas, who is a professor of hematology and oncology. “With today’s approval by the FDA, physicians will be able to identify patients who are candidates for receiving pembrolizumab as first-line therapy.”

As part of a phase III clinical trial, Ribas and colleagues enrolled 834 patients with metastatic melanoma who were randomly assigned to pembrolizumab and ipilimumab. The team assessed treatment responses by two criteria, progression-free survival (PFS, or the length of time before a patient’s cancer worsens) and overall survival. Ribas and colleagues also assessed patient overall response rate to treatment and safety.

Results showed that after six months, 45 percent of those taking pembrolizumab, compared to 26 percent adminstered ipilimumab, responded to therapy (representing a 42 percent improvement in progression free survival for patients on pembrolizumab). Overall survival at one year for patients who received pembrolizumab was 74 and 68 percent in two study groups, compared with 58 percent for those who received ipilimumab (representing an improvement of 34 percent).

In addition, the tumor response rate was 33 percent for pembrolizumab and 12 percent for ipilimumab. Adverse side effects were also lower for patients receiving pembrolizumab (12 percent) compared with ipilimumab (20 percent).

How does Keytruda work?

Keytruda, formerly known as MK-3475, is an antibody that targets a protein called PD-1 that is expressed by immune cells. The protein puts the immune system’s brakes on, keeping its T cells from recognizing and attacking cancer cells, said Dr. Antoni Ribas.

For many years, when using immunotherapy to fight cancer, doctors’ strategy has been to bolster the immune system so it could kill the cancer cells. But the approach had limited success because PD-1 prevented the immune system from becoming active enough to attack the cancer.

Keytruda, in effect, cuts the brake lines, freeing up the immune system to attack the cancer.

The study was published in the New England Journal of Medicine in April 2015.

Survivor Story

Tom Stutz, 74, of Sherman Oaks, California, was diagnosed in June 2011 with melanoma that had spread to his lung, liver and other parts of his body. He didn’t see how he could survive, but he decided to enroll in the clinical trial of Keytruda anyway.

“I wasn’t eating. I was on oxygen. I couldn’t walk,” he said. “When I went into the hospital at the end of May [2012], I didn’t think I was coming out.”

Gradually, though, Stutz started feeling better. Today, he’s no longer on oxygen and walks several miles every day.

“It’s the little things that make me happy now,” Stutz said. “I’m very appreciative that I get to get up in the morning, go into my backyard and see my garden. I’m able to be with my children and grandchildren, go on vacations with them. I was close to the end of the road, as far as you can get to the edge of the cliff, and I was pulled back by this treatment.”

For more information about Keytruda clinical trials at UCLA, members of the public are invited to call 888-798-0719.

Source: Press releaseUCLA Jonsson Comprehensive Cancer Centre

 

3 replies

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s